The impact of palivizumab reimbursement criteria on neonatal RSV hospitalizations and drug prescriptions: an area-based cohort study from the Tuscany Region, Italy
 
More details
Hide details
1
Epidemiology Unit, Meyer Children’s Hospital, Florence, Italy
 
2
Observatory of Epidemiology, Regional Health Agency of Tuscany, Florence, Italy
 
3
Medical Specialization School of Hygiene and Preventive Medicine, University of Florence, Italy
 
4
Neonatal Intensive Care Unit, Meyer Children’s Hospital, Florence, Italy
 
 
Publication date: 2023-04-26
 
 
Popul. Med. 2023;5(Supplement):A1198
 
ABSTRACT
Background and Objective:
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants aged 29 weeks. The study aimed to evaluate the impact of the 2016 restrictions (intervention) on RSV hospitalizations and palivizumab prescriptions for infants aged

ISSN:2654-1459
Journals System - logo
Scroll to top